• Above all, we make a difference.
  • Metastatic Breast Cancer References


    1. American Cancer Society. Breast Cancer Facts & Figures 2015-2016, 2015.
    2. Howlader N, Noone AM, Krapcho M, et al., editors. SEER Fast Stats, 1975-2013. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/faststats/, 2016.
    3. Lobbezoo DJ, van Kampen RJ, Voogd AC, et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 112(9):1445-51, 2015.
    4. Lippman ME. Chapter 74: Management summary for the care of patients with metastatic breast cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. V.2.2016. http://www.nccn.org, 2016.
    6. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R for the Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 19(2):343-53, 2001.
    7. Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol. 34(25):3069-103, 2016.
    8. Turner NC, Ro J, André F, et al. for the PALOMA3 Study Group. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 373(3):209-19, 2015.
    9. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 375:1925-1936, 2016.
    10. U.S. Food and Drug Administration. FDA approves Ibrance for postmenopausal women with advanced breast cancer. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm432871.htm, 2015.
    11. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 375(18):1738-1748, 2016.
    12. U.S. Food and Drug Administration. Ribociclib (Kisqali). https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm546438.htm, 2017.
    13. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med. 366(6):520-9, 2012.
    14. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 30(22):2718-24, 2012.
    15. Esserman LJ and Joe BN. Clinical features, diagnosis, and staging of newly diagnosed breast cancer, in Up-to-Date (Burstein H, Vora SR, eds.). Up-to-Date, 2017.
    16. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344: 783-92, 2001.
    17. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 29(3):264-71, 2011.
    18. Gelmon KA, Boyle FM, Kaufman B, et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast Cancer: final results of NCIC CTG MA.31. J Clin Oncol. 33(14):1574-83, 2015.
    19. Swain SM, Baselga J, Kim SB, et al. for the CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 372(8):724-734, 2015.
    20. Verma S, Miles D, Gianni L, et al. for the EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 367(19):1783-91, 2012.
    21. U.S. Food and Drug Administration. FDA label Kadcyla. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf, 2013.
    22. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 355(26):2733-43, 2006.
    23. Guan Z, Xu B, DeSilvio ML, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol. 31(16):1947-53, 2013.
    24. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 27(33):5538-46, 2009.
    25. Schwartzberg LS, Franco SX, Florance A, O'Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist. 15(2):122-9, 2010.
    26. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 30(21):2585-92, 2012.
    27. Toi M, Iwata H, Fujiwara Y, et al. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer. 101(10):1676-82, 2009.
    28. Sutherland S, Ashley S, Miles D, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases - the UK experience. Br J Cancer. 102(6):995-1002, 2010.
    29. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 14(1):64-71, 2013.
    30. Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2:CD003474, 2012.
    31. Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 19(8):1407-16, 2008.
    32. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 19(3):420-32, 2008.
    33. National Academy of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, D.C.: The National Academies Press, 2017.
    34. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cancer-related fatigue. V.1.2016. http://www.nccn.org, 2016.
    35. Headley JA, Ownby KK, John LD. The effect of seated exercise on fatigue and quality of life in women with advanced breast cancer. Oncol Nurs Forum. 31(5):977-83, 2004.
    36. Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol. 26(4):592-8, 2008.
    37. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 26(1):132-49, 2008.
    38. Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst. 101(23):1633-41, 2009.
    39. Chavez-MacGregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. Cancer. 117(16):3641-9, 2011.
    40. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 361(2):123-34, 2009.
    41. U.S. Food and Drug Administration. Questions and Answers: Removing metastatic breast cancer as an indication from Avastin’s product labeling. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280536.htm, 2011.
    42. U.S. Food and Drug Administration. Information for consumers (biosimilars). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm241718.htm, 2015.
    43. Rugo HS, Barve A, Waller CF, et al. for the Heritage Study Investigators. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA. 317(1):37-47, 2017.
    44. Heery CR, Ibrahim NK, Arlen PM, et al. Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial. JAMA Oncol. 1(8):1087-95, 2015.
    45. Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 34(21):2460-7, 2016.
    46. Cristofanelli M, Budd GT, Ellis MJ, Stopeck AS, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351(8):781-91, 2004.
    47. Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 15(4):406-14, 2014.
    48. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 368(13):1199-209, 2013.
    49. Visvanathan K, Fackler MS, Zhang Z, et al. Monitoring of serum DNA methylation as an early independent marker of response and survival in metastatic breast cancer: TBCRC 005 prospective biomarker study. J Clin Oncol. 35(7):751-758, 2017.
    50. Harris L, Fritsche H, Mennel R, et al. for the American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25(33):5287-312, 2007.
    51. Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 32(31):3483-9, 2014.
    52. Hayes DF. Systemic treatment for metastatic breast cancer: general principles, in Up-to-Date (Burstein H, Vora SR, eds.). Up-to-Date, 2016.
    53. World Health Organization. WHO Definition of palliative care. http://www.who.int/cancer/palliative/definition/en/, 2016.
    54. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 363(8):733-42, 2010.
    55. Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol. 30(8):880-7, 2012.
    56. National Cancer Institute. Pain control: Support for people with cancer. http://www.cancer.gov/publications/patient-education/paincontrol.pdf, 2014.
    57. American Cancer Society. Developing a pain control plan. http://www.cancer.org/treatment/treatmentsandsideeffects/physicalsideeffects/pain/developing-a-pain-control-plan, 2015.
    58. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Adult cancer pain V.2.2016. http://www.nccn.org/, 2016.
    59. Goodwin PJ. Support groups in advanced breast cancer. Cancer. 104(11 Suppl):2596-601, 2005.
    60. Cheng MJ and Smith TJ. Chapter 73: Palliative care in breast cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    61. U.S. Department of Health and Human Services and Centers for Medicare & Medicaid Services. Medicare Part A coverage - hospice. https://www.medicare.gov/what-medicare-covers/part-a/part-a-coverage-hospice.html, 2016.
    62. Grunfeld E, Coyle D, Whelan T, et al. Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ. 170(12):1795-801, 2004.
    63. Bakitas M, Ahles TA, Skalla K, et al. for the ENABLE project team. Proxy perspectives regarding end-of-life care for persons with cancer. Cancer. 112(8):1854-61, 2008.
    64. Mack JW, Weeks JC, Wright AA, Block SD, Prigerson HG. End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol. 28(7):1203-8, 2010.  
    65. Mariotto AB, Etzioni R, Hurlbert M, PenberthyL, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 26(6):809-815, 2017.
    66. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 377(6):523-533, 2017.
    67. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 35(25):2875-2884, 2017.
    68. Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res. 23(17):5218-5224, 2017.
    69. U.S. Food and Drug Administration (FDA). FDA approves new treatment for certain advanced or metastatic breast cancers. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm578071.htm, 2017.

    Updated 12/06/17


    Metastatic Breast Cancer



Tools & Resources


Related Video



1-877 GO KOMEN